Edition:
United Kingdom

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

138.26USD
8:03pm GMT
Change (% chg)

$1.79 (+1.32%)
Prev Close
$136.46
Open
$137.87
Day's High
$138.93
Day's Low
$134.16
Volume
100,561
Avg. Vol
172,927
52-wk High
$195.97
52-wk Low
$79.90

Chart for

About

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and... (more)

Overall

Beta: --
Market Cap(Mil.): $2,399.97
Shares Outstanding(Mil.): 37.44
Dividend: --
Yield (%): --

Financials

  SAGE.OQ Industry Sector
P/E (TTM): -- 69.71 33.71
EPS (TTM): -6.05 -- --
ROI: -85.13 8.99 14.48
ROE: -85.28 10.13 15.99

Sage shares soar after oral postpartum depression treatment succeeds in trial

Sage Therapeutics Inc said on Monday its oral treatment for postpartum depression met the main goal of reducing symptoms of the condition, when compared to a placebo in a late-stage study, sending its shares up 33 percent.

07 Jan 2019

UPDATE 1-Sage shares soar after oral postpartum depression treatment succeeds in trial

Jan 7 Sage Therapeutics Inc said on Monday its oral treatment for postpartum depression met the main goal of reducing symptoms of the condition, when compared to a placebo in a late-stage study, sending its shares up 33 percent.

07 Jan 2019

Sage's oral postpartum depression treatment succeeds in late-stage study

Jan 7 Sage Therapeutics Inc said on Monday its oral treatment for postpartum depression met the main goal of reducing symptoms of the condition, when compared to a placebo in a late-stage study.

07 Jan 2019

FDA panel recommends Sage's postpartum depression treatment

An advisory panel to the U.S. Food and Drug Administration on Friday recommended Sage Therapeutics Inc's experimental treatment for postpartum depression, saying the benefits of the drug outweighed risks.

02 Nov 2018

UPDATE 2-FDA panel recommends Sage's postpartum depression treatment

Nov 2 An advisory panel to the U.S. Food and Drug Administration on Friday recommended Sage Therapeutics Inc's experimental treatment for postpartum depression, saying the benefits of the drug outweighed risks.

02 Nov 2018

Sage's postpartum depression treatment benefits outweigh risk: FDA panel

Nov 2 The benefits of Sage Therapeutics Inc's experimental treatment for postpartum depression outweigh risks, an advisory panel to the U.S. Food and Drug Administration said on Friday.

02 Nov 2018

Earnings vs. Estimates